EVAX Stock Performance, Insider Transaction and News

EVAX - Evaxion Biotech A/S

Market Cap	34M	P/E	-	EPS this Y	74.30%	Ern Qtrly Grth	-
Income	-22.12M	Forward P/E	-0.63	EPS next Y	100.50%	50D Avg Chg	-8.00%
Sales	73k	PEG	-	EPS past 5Y	-	200D Avg Chg	-25.00%
Dividend	N/A	Price/Book	3.58	EPS next 5Y	-	52W High Chg	-65.00%
Recommedations	1.70	Quick Ratio	0.94	Shares Outstanding	5.22M	52W Low Chg	34.00%
Insider Own	16.60%	ROA	-79.47%	Shares Float	36.13M	Beta	-0.02
Inst Own	0.93%	ROE	-1,238.11%	Shares Shorted/Prior	42.58K/27.53K	Price	1.23
Gross Margin	100.00%	Profit Margin	-	Avg. Volume	214,493	Target Price	11.75
Oper. Margin	-5,978.08%	Earnings Date	May 29	Volume	18,325	Change	-2.38%

Healthcare | Biotechnology | Denmark

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Evaxion Biotech A/S News

04/17/24	Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
04/03/24	Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
04/03/24	Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
04/02/24	Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
03/27/24	Evaxion Announces Business Update and Full Year 2023 Financial Results
03/22/24	When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?
03/19/24	Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
02/29/24	Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
07:30 AM	Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
02/07/24	Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
02/06/24	Evaxion Announces Closing of $15 Million Public Offering
02/01/24	Evaxion Biotech Announces Pricing of $15 Million Public Offering
01/24/24	Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
01/22/24	Evaxion Announces Completion of ADS Ratio Change
01/08/24	Evaxion Announces Plan to Implement ADS Ratio Change
12/21/23	Evaxion Biotech Announces Closing of Private Placement
12/19/23	Evaxion Announces Business Update and Third Quarter 2023 Financial Results
12/19/23	Evaxion Biotech Announces Private Placement Financing
11/28/23	Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
11/15/23	Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy

EVAX Chatroom

Olsen71 Posted - 1 day ago

$EVAX 🚀🏖🍾

Stevejobsofficial Posted - 1 day ago

$EVAX word

briefingcom Posted - 2 days ago

$EVAX: Evaxion Biotech announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240417080336EVAX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 2 days ago

$EVAX Evaxion Biotech says first patient completed dosing with personalized EVX-01 Evaxion Biotech announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA. The Company initiated its Phase 2 clinical study in September 2022 to assess the efficacy, safety and ability to induce a tumor-specific immune response of the EVX-01 cancer vaccine in metastatic melanoma patients. The EVX-01 vaccine was designed using Evaxion's proprietary AI-Immunology platform and is an individualized therapy matching the unique tumor profile and characteristics of the patient's immune system. Each patient enrolled in the trial receives a unique vaccine designed and manufactured based on their individual biology. Patients are administered ten EVX-01 doses over a period of 78 weeks in combination with the anti-PD-1 therapy, KEYTRUDA. At the end of 2023, Evaxion reported initial EVX-01 Phase 2 data confirming the favorable safety profile and promising immunological data as observed in the previously successful Phase 1 clinical trial.

Stock_Titan Posted - 2 days ago

$EVAX Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 https://www.stocktitan.net/news/EVAX/evaxion-announces-phase-2-clinical-trial-update-first-patient-wi81o257ly5w.html

Catracho5 Posted - 3 days ago

$EVAX When $10+?🤔

Jalvarez509 Posted - 1 week ago

$EVAX

Infamousmc13 Posted - 1 week ago

$EVAX 🔥🩳🔥